Hadassah

Initiated in Israel, Clinical Trial for Innovative Pancreatic Cancer Treatment Expands to United States

Saturday, Dec 1 2012

A clinical trial with TL-118--a new treatment for metastatic pancreatic cancer--that has been ongoing at the Hadassah University Medical Center and three other oncology centers in Israel, has been expanded to the United States.

TL-118. produced by Tiltan Pharma Ltd., belongs to the family of angiogenesis-inhibiting drugs, which means it inhibits new blood vessel formation in tumors and thus cuts off their blood supply and growth. Angiogenesis, the process by which new blood vessels are formed, is a hallmark capability of cancer cells. Anti-angiogenic therapy has, therefore, emerged as a most promising strategy with solid tumors, which rely on aggressive angiogenesis for their growth.

The new United States trial will be conducted at White Plains (NY) Hospital, and will include patients who have been newly diagnosed with metastatic pancreatic cancer and not yet treated with any chemotherapy. A control group will receive standard chemotherapy, while the treatment group will receive TL-118 in addition to chemotherapy.

Dr. Dan Costin, Co-Medical Director of the White Plains Hospital cancer program and Principal Investigator for the TL-118 study at White Plains Hospital, related: "We are happy to introduce this cutting-edge therapy to our pancreatic cancer patients. Unfortunately, metastatic pancreatic cancer is a disease with very poor prognosis and we are urgently seeking new solutions that might enhance survival."

TL-118 was initially tested in a mouse model of pancreatic cancer. In these pre-clinical studies, TL-118 monotherapy inhibited tumor growth significantly, as compared to the standard-of-care chemotherapy. Moreover, when TL-118 therapy was combined with standard-of-care chemotherapy, the tumors were eliminated in all the treated animals.

To date, over 100 cancer patients have been treated with TL-118 for up to four years, according to Tiltan Pharma, jointly owned by Yissum, the Hebrew University's Technology Transfer Company, and other investors from Israel and Canada.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Sep 21 2018

Hadassah Numbers to Commend and Celebrate

Over the past year, Hadassah Medical Center researchers received over 60 percent of the National Science Foundation Awards for biomedical research in Israeli hospitals...

READ MORE ›
alt_text

Thursday, Sep 20 2018

NanoKnife® Technology to Treat Prostate Cancer Comes to Hadassah

NanoKnife® technology, the most innovative method for treatment of localized prostate cancer, is now being applied at the Hadassah Medical Organization, making Hadassah the first in Israel to treat prostate cancer in this minimally invasive way.

READ MORE ›
alt_text

Thursday, Sep 20 2018

Car-ramming Victim and His Family Give Thanks

Life in the Horaling family changed forever on November 17, 2017. Dad Ebenezer Horaling, 35, was taking a bus to work as a custodian at a boys’ junior high school 20 minutes away from his home. Ebenezer had gotten off the bus and was walking to the school when a 17-year-old terrorist drove into him, throwing him into the air.

READ MORE ›
alt_text

Thursday, Sep 20 2018

Hadassah Director General Organizes Surprise for Hospitalized Children

Providing a respite from medical treatment during this holiday season, a collection of antique cars suddenly appeared on the lawns of Hadassah Hospital Ein Kerem, and the hospitalized children and their families were invited to take a close look.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More